Roth Capital lowered the firm’s price target on PolyPid (PYPD) to $9 from $10 and keeps a Buy rating on the shares following the Q3 report. The firm expects a positive pre-new drug application meeting and a potential filing submission in the first half of 2026 for PolyPid. Given that D-PLEX100 “enjoys multiple designations” from the FDA, it should get a six-month review, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PYPD:
- PolyPid Ltd. Advances Towards Key Milestones in 2025
- PolyPid Ltd. Earnings Call: Progress and Potential
- PolyPid’s Promising Future: Buy Rating Backed by D-PLEX100 Progress and Expanding Drug Delivery Pipeline
- PolyPid Advances D-PLEX₁₀₀ Towards FDA Submission and Commercial Readiness
- PolyPid sees cash runway ‘well into’ 2026